Trine Jakobi Nøttrup, MD, PhD, on BRCA Wild-Type Recurrent Ovarian Cancer: Novel Triplet Maintenance Regimen

November 04, 2026

Trine Jakobi Nøttrup, MD, PhD, of Rigshospitalet, describes findings from the DOVACC trial, which evaluated the combination of olaparib, durvalumab, and UV1—a therapeutic cancer vaccine directed against human telomerase reverse transcriptase—as maintenance therapy in patients with BRCA wild-type recurrent ovarian cancer (Abstract LBA39). 

Related Content